gsk defence is in todays fin review,they seem to be contradicting themselves by saying sales were weak due to inhaler,BUT,the inhaler is great in 2001,and that they admit to under funding on promotion, pay up gsk while your still out of court,or else biota will be front page news when bird flu hits,e.g GSK HIDES RELENZA FROM THOSE MOST IN NEED.............................
- Forums
- ASX - By Stock
- BTA
- new drug on top of gsk weak defence
new drug on top of gsk weak defence
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)